These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

280 related articles for article (PubMed ID: 17679817)

  • 1. High cardiovascular risk in patients with diabetes and the cardiometabolic syndrome: mandate for statin therapy.
    Gonzalez GL; Manrique CM; Sowers JR
    J Cardiometab Syndr; 2006; 1(3):178-83. PubMed ID: 17679817
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Management of cardiovascular risk in patients with type 2 diabetes mellitus as a component of the cardiometabolic syndrome.
    Ferdinand KC
    J Cardiometab Syndr; 2006; 1(2):133-40. PubMed ID: 17679832
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Beyond low-density lipoprotein: addressing the atherogenic lipid triad in type 2 diabetes mellitus and the metabolic syndrome.
    Nesto RW
    Am J Cardiovasc Drugs; 2005; 5(6):379-87. PubMed ID: 16259526
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pitavastatin in cardiometabolic disease: therapeutic profile.
    Masana L
    Cardiovasc Diabetol; 2013; 12 Suppl 1(Suppl 1):S2. PubMed ID: 23819752
    [TBL] [Abstract][Full Text] [Related]  

  • 5. New treatment options for lipid-lowering therapy in subjects with type 2 diabetes.
    Scicali R; Di Pino A; Ferrara V; Urbano F; Piro S; Rabuazzo AM; Purrello F
    Acta Diabetol; 2018 Mar; 55(3):209-218. PubMed ID: 29260404
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Statins in cardiometabolic disease: what makes pitavastatin different?
    Ginsberg H
    Cardiovasc Diabetol; 2013; 12 Suppl 1(Suppl 1):S1. PubMed ID: 23819727
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Liraglutide Reduces Cardiovascular Events and Mortality in Type 2 Diabetes Mellitus Independently of Baseline Low-Density Lipoprotein Cholesterol Levels and Statin Use.
    Verma S; Leiter LA; Mazer CD; Bain SC; Buse J; Marso S; Nauck M; Zinman B; Bosch-Traberg H; Rasmussen S; Michelsen MM; Bhatt DL
    Circulation; 2018 Oct; 138(15):1605-1607. PubMed ID: 30354517
    [No Abstract]   [Full Text] [Related]  

  • 8. [Diabetic dyslipidaemia and the atherosclerosis].
    Márk L; Dani G
    Orv Hetil; 2016 May; 157(19):746-52. PubMed ID: 27133274
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The gap between the current dyslipidemia guidelines and the physicians' treatment targets in patients with type 2 diabetes in Turkey.
    Kahya Eren N; Harman E; Dolek D; Emren S; Tütüncüoğlu AP; Nazli C; Ergene O
    Minerva Cardioangiol; 2014 Jun; 62(3):287-95. PubMed ID: 24831765
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Association of Fenofibrate Therapy With Long-term Cardiovascular Risk in Statin-Treated Patients With Type 2 Diabetes.
    Elam MB; Ginsberg HN; Lovato LC; Corson M; Largay J; Leiter LA; Lopez C; O'Connor PJ; Sweeney ME; Weiss D; Friedewald WT; Buse JB; Gerstein HC; Probstfield J; Grimm R; Ismail-Beigi F; Goff DC; Fleg JL; Rosenberg Y; Byington RP;
    JAMA Cardiol; 2017 Apr; 2(4):370-380. PubMed ID: 28030716
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Lipid-lowering cardiovascular prevention in type 2-diabetes. Statins are effective according to the FIELD study].
    Båvenholm P; Attvall S; Nilsson PM
    Lakartidningen; 2006 Aug 30-Sep 5; 103(35):2462-6. PubMed ID: 17002161
    [No Abstract]   [Full Text] [Related]  

  • 12. Lipid goals in metabolic syndrome and diabetes.
    Colhoun HM
    Curr Atheroscler Rep; 2007 Oct; 9(4):286-95. PubMed ID: 18173956
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Management of dyslipidemias in patients with diabetes and chronic kidney disease.
    Molitch ME
    Clin J Am Soc Nephrol; 2006 Sep; 1(5):1090-9. PubMed ID: 17699330
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Dyslipidemia in type 2 diabetes mellitus.
    Gadi R; Samaha FF
    Curr Diab Rep; 2007 Jun; 7(3):228-34. PubMed ID: 17547840
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Management of dyslipidemia in the metabolic syndrome: recommendations of the Spanish HDL-Forum.
    Ascaso J; Gonzalez Santos P; Hernandez Mijares A; Mangas Rojas A; Masana L; Millan J; Pallardo LF; Pedro-Botet J; Perez Jimenez F; Pintó X; Plaza I; Rubiés J; Zúñiga M
    Am J Cardiovasc Drugs; 2007; 7(1):39-58. PubMed ID: 17355165
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clinical significance of recent lipid trials on reducing risk in patients with type 2 diabetes mellitus.
    Jones PH
    Am J Cardiol; 2007 Feb; 99(4A):133B-140B. PubMed ID: 17307065
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Utilization of lipid-modifying therapy and low-density lipoprotein cholesterol goal attainment in patients at high and very-high cardiovascular risk: Real-world evidence from Germany.
    März W; Dippel FW; Theobald K; Gorcyca K; Iorga ŞR; Ansell D
    Atherosclerosis; 2018 Jan; 268():99-107. PubMed ID: 29197254
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Drug insight: the role of statins in combination with ezetimibe to lower LDL cholesterol.
    Gotto AM; Farmer JA
    Nat Clin Pract Cardiovasc Med; 2006 Dec; 3(12):664-72. PubMed ID: 17122799
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Management of dyslipidemia in diabetes.
    Solano MP; Goldberg RB
    Cardiol Rev; 2006; 14(3):125-35. PubMed ID: 16628021
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pharmacotherapy of mixed dyslipidemia in the metabolic syndrome.
    Nakajima K
    Curr Clin Pharmacol; 2010 May; 5(2):133-9. PubMed ID: 20156152
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.